LexaGene Holdings Inc.

Overview

• IndustrySurgical & Medical Instruments & Apparatus²
• HeadquartersBeverly, United States²
• Incorporated inBritish Columbia, Canada³
• Business address500 Cummings Ctr., Suite 4550, Beverly, Ma 01915³
• Filer category, Emerging growth company³
• Legal formCorporation²
• LEI529900GAYVSL5JI2WX16²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressSuite 1500, 1055 West Georgia Street, V6E 4N7 Vancouver, Canada²

See how the biggest companies compare on our leaderboards

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• CFOJEFFREY MITCHELL named Feb 16, 2022 to Nov 16, 2022⁴
• CEOJOHN (JACK) REGAN named Feb 16, 2022 to Nov 16, 2022⁴
• COOSTEVEN ARMSTRONG named Feb 16, 2022 to Nov 16, 2022⁴
• DirectorJANE SYKES named Feb 16, 2022 to Nov 16, 2022⁴
• DirectorJOSEPH CARUSO named Feb 16, 2022 to Nov 16, 2022⁴
• DirectorSTEPHEN MASTROCOLA named Feb 16, 2022 to Nov 16, 2022⁴
• DirectorTHOMAS SLEZAK named Feb 16, 2022 to Nov 16, 2022⁴

Former names

• STONESHIELD CAPITAL CORP.Jul 29, 2010 to Jul 29, 2010³
• STONESHIELD CAPITAL CORPNov 12, 2008 to Nov 12, 2008³

Timeline

1. Feb 24, 20238-K Bankruptcy or receivership; Regulation FD disclosure⁵
2. Feb 8, 20238-K Regulation FD disclosure⁶
3. Feb 8, 20238-K Shareholder vote; Other events⁷
4. Jan 18, 20238-K Regulation FD disclosure⁸
5. Dec 16, 20228-K Regulation FD disclosure⁹
6. Dec 7, 20228-K Regulation FD disclosure¹⁰
7. Nov 22, 20228-K Regulation FD disclosure¹¹
8. Nov 2, 20228-K New debt or obligation; Regulation FD disclosure¹²
9. Oct 28, 20228-K Regulation FD disclosure¹³
10. Oct 26, 20228-K Entered a material agreement¹⁴

Filings

26 filings to the SEC since October 2021: 2 quarterly reports, 10 major events, 4 private raises, 10 other. The latest 20:

1. Apr 10, 2025REVOKED EDGAR
2. Feb 24, 20238-K EDGAR
3. Feb 9, 2023S-8 EDGAR
4. Feb 8, 20238-K EDGAR
5. Feb 8, 20238-K EDGAR
6. Jan 18, 20238-K EDGAR
7. Jan 17, 202310-Q EDGAR
8. Dec 30, 2022DEFA14A EDGAR
9. Dec 30, 2022DEF 14A EDGAR
10. Dec 16, 20228-K EDGAR
11. Dec 7, 20228-K EDGAR
12. Nov 22, 20228-K EDGAR
13. Nov 16, 2022D EDGAR
14. Nov 2, 20228-K EDGAR
15. Oct 28, 20228-K EDGAR
16. Oct 26, 20228-K EDGAR
17. Oct 18, 202210-Q EDGAR
18. Oct 18, 2022NT 10-Q EDGAR
19. Aug 26, 2022UPLOAD EDGAR
20. Aug 9, 2022CORRESP EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Nov 1, 2022Raised $1.6 million in a private offering of debt⁴ Form D: 1 investor so far Form D
2. Feb 7, 2022Raised $3.5 million in a private offering of equity¹⁵ Form D: $8.1 million offered in all Form D
3. Feb 7, 2022Raised $5 million in a private offering of equity¹⁶ Form D: $11.5 million offered in all Form D

SEC filer profile

How LexaGene Holdings Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARLexaGene Holdings Inc.¹
• CIK0001450416
• Filer status<br>emerging growth company¹
• Incorporated inBritish Columbia, Canada¹
• Fiscal year endsFebruary 28¹
• Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address500 Cummings Ctr., Suite 4550, Beverly, MA 01915¹
• Phone800-215-1824¹
• Shares outstanding140,641,855 as of Jan 17, 2023¹⁷
• On EDGAR sinceNov 12, 2008¹
• Filings31 in all: 8-K (10), D (6), 10-Q (2), D/A (2), UPLOAD (2), 10-12G (1), 10-12G/A (1), CORRESP (1)¹
  All 14 form types

  DEF 14A (1), DEFA14A (1), NT 10-Q (1), REGDEX (1), REVOKED (1), S-8 (1)

• Latest filingsQuarterly report (10-Q) Jan 17, 2023
  Proxy statement (DEF 14A) Dec 30, 2022
  Latest 8-K (8-K) Feb 24, 2023